Patients who stop taking semaglutide regain most of the weight they lost within a year, and the nausea that comes with staying on the drug pushes a significant share of users to quit. Those two problems, weight rebound and poor tolerability, have set off a competitive sprint among drugmakers to develop next-generation obesity treatments that work through different biological pathways. At least five distinct drug candidates are now in clinical trials, each betting on a mechanism that could deliver durable weight loss without the gastrointestinal side effects that define the current generation of GLP‑1 therapies.
Weight rebound after semaglutide and tirzepatide sets the stakes
The clearest evidence for the durability problem comes from the STEP 1 trial extension, which tracked participants through 68 weeks on semaglutide 2.4 mg followed by 52 weeks off the drug. After stopping treatment, participants experienced substantial weight regain and reversal of the cardiometabolic improvements they had achieved, as detailed in the long-term follow-up. Blood pressure, lipid levels, and glycemic markers all drifted back toward baseline once injections stopped.
The pattern was not unique to semaglutide. The STEP 4 trial used a randomized withdrawal design, comparing adults who continued weekly treatment against those switched to placebo after a run‑in period. Participants who remained on semaglutide maintained and in some cases deepened their weight loss, while those randomized to placebo regained a clinically significant share of the pounds they had shed, according to the withdrawal analysis. The divergence between the two groups emerged quickly, underscoring how tightly weight trajectories are coupled to ongoing drug exposure.
The same rebound dynamic showed up in SURMOUNT‑4, a randomized trial that tested continued tirzepatide treatment for maintenance of weight reduction. Adults who stayed on tirzepatide largely preserved their prior losses, while those switched to placebo began regaining weight within weeks, a pattern documented in the maintenance study. Across these trials, cardiometabolic benefits tracked the weight curve, fading as pounds returned.
Taken together, these three trials establish a consistent finding: current incretin-based obesity drugs require indefinite use to maintain results. That reality creates a two-sided pressure. Patients face a long-term commitment to injectable therapy, and many who experience persistent nausea, vomiting, or diarrhea abandon treatment before reaching their weight-loss goals. Clinicians must balance powerful efficacy against side-effect burdens that can erode adherence over time. The commercial and clinical incentive to solve both problems at once is driving a wave of experimental programs.
Five drug candidates chasing better tolerability and durability
The next wave of obesity drugs splits along several biological strategies. Some candidates double down on incretin pathways in search of even greater efficacy, while others try to bypass GLP‑1 altogether.
Retatrutide, a triple-hormone-receptor agonist targeting GLP‑1, GIP, and glucagon receptors, produced striking weight loss in a phase 2 trial published in the New England Journal of Medicine. Participants on higher doses lost a larger percentage of their body weight than typically seen with existing GLP‑1 agonists, but the trial also enumerated dose-related gastrointestinal adverse events, including nausea, vomiting, diarrhea, and constipation, suggesting that adding a third receptor target did not eliminate the tolerability burden. Investigators reported that careful dose escalation reduced, but did not remove, these symptoms, leaving phase 3 trials to determine whether titration can manage side effects at scale without blunting efficacy.
AMG 133 takes a different approach, pairing GLP‑1 receptor agonism with GIP receptor antagonism rather than activation. In theory, blocking GIP could modulate insulin and glucagon secretion in a way that enhances weight loss while altering the side-effect profile. Phase 1 data published in Nature Medicine showed the drug produced meaningful weight reduction over several months and reported GI symptom patterns including nausea and vomiting in early-phase participants. The study was not powered to make firm tolerability comparisons against semaglutide or tirzepatide, so whether antagonizing the GIP receptor changes the balance between efficacy and side effects in larger, longer trials remains an open question.
Orforglipron, a daily oral GLP‑1 receptor agonist, represents a convenience play within the same biological pathway. A phase 2 trial in adults with obesity found dose-dependent weight loss approaching that of injectable GLP‑1 drugs at higher doses. The study also reported nausea and vomiting incidence ranges across dose groups and documented discontinuation rates due to adverse events, underscoring that the pill format does not inherently solve GLP‑1’s GI issues. For patients who dislike injections or struggle with weekly dosing, however, a once-daily oral option could improve adherence, especially if future formulations allow for flexible titration or combination with other agents.
The most intriguing departure from GLP‑1 biology may be eloralintide, a selective amylin receptor agonist. Amylin is a pancreatic hormone co-secreted with insulin that promotes satiety and slows gastric emptying, but through receptor systems distinct from GLP‑1. A 48‑week phase 2 trial published in The Lancet reported dose-specific nausea percentages and other adverse event patterns across treatment arms, with GI symptoms generally clustered early in treatment and attenuating over time. Because amylin signaling engages different neural circuits in the brainstem and hypothalamus, researchers hope that amylin-receptor agonists can deliver appetite suppression with a narrower GI side-effect footprint.
That biological difference underpins a testable hypothesis: in head‑to‑head phase 3 trials, amylin agonists like eloralintide could show meaningfully lower rates of treatment discontinuation due to GI effects than GLP‑1 agonists, even if some nausea remains. If that holds true while preserving double‑digit percentage weight loss, amylin-based drugs could emerge as preferred long-term maintenance therapies, particularly for patients who have already cycled off GLP‑1 drugs because of side effects.
A separate strategy sidesteps the tolerability question entirely by focusing on body composition rather than absolute weight. One experimental agent now in phase 2 aims to preserve or even increase lean mass while selectively reducing fat mass, essentially trying to reshape the body even if the scale moves less dramatically. Early data from a randomized trial published in Nature Medicine suggest that combining a modest appetite suppressant with an anabolic signal to muscle can shift the ratio of fat to lean tissue in a favorable direction. Participants lost less total weight than typically seen with semaglutide, but dual‑energy X‑ray absorptiometry scans showed a higher proportion of that loss came from fat, with relative preservation of muscle.
If these findings hold up in larger cohorts, body-composition drugs could appeal to patients and clinicians worried about sarcopenia, frailty, or long-term metabolic consequences of losing muscle. They may also be easier to tolerate, because they do not need to drive extreme appetite suppression or profound slowing of gastric emptying to achieve their goals. In that scenario, such agents might be paired with lower doses of GLP‑1 or amylin agonists, using combination regimens to balance efficacy, durability, and day‑to‑day comfort.
What success would look like in the next generation
Across these programs, success will be measured on several axes at once. Regulators and clinicians will look for weight loss that meets or exceeds current GLP‑1 benchmarks, cardiometabolic improvements that persist beyond the first year, and safety profiles that support multi‑year or even lifelong use. Just as important will be real‑world persistence: the share of patients still on therapy after one, two, or three years, and the reasons they stay or leave.
For now, the evidence from semaglutide and tirzepatide makes one conclusion unavoidable: obesity behaves more like a chronic, relapsing condition than a short-term problem to be fixed and forgotten. The next generation of drugs will have to fit that reality, offering not just impressive weight-loss curves in year one but sustainable, tolerable regimens that people can live with for the long haul.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
